ReviewMechanobiology in medicine2026
From biomechanical mechanisms to clinical reasoning: Deciphering mechanobiological drivers of aortic valve calcification for precision therapy.
Review in Mechanobiology in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcific aortic valve disease (CAVD) is a degenerative cardiovascular disorder characterized by progressive valvular thickening and calcification, ultimately leading to aortic stenosis, heart failure, and high mortality. Despite associations with hyperlipidemia, inflammation, and bicuspid aortic valve (BAV) malformation, no targeted pharmacotherapies exist, indicating unaddressed core pathogenic mechanisms. The aortic valve is composed of valvular interstitial cells (VICs) and endothelial cells (VECs) which are constantly exposed to hemodynamic forces, with progressive extracellular matrix (ECM) stiffening during CAVD-two mechanobiological pillars closely linked to pathogenesis. This article synthesizes current mechanobiology research on CAVD and bridges biomechanical insights with clinical practice to dissect precision interventions. Clinical and experimental evidence confirms abnormal hemodynamics (e.g., oscillatory shear stress, elevated blood pressure) and increased ECM stiffness drive CAVD by modulating VIC phenotypic transition (osteogenic differentiation, myofibroblastic transformation), VEC dysfunction (epithelial-mesenchymal transition, inflammation), and ECM remodeling/apoptosis. These effects are mediated by chemical pathways (Transforming growth factor-β1(TGF-β1), YAP, Notch1/Runt-related transcription factor 2 (Runx2), Wnt/β-catenin) and cytoskeleton/nucleoskeleton-dependent mechanotransduction (integrin-linker of the nucleoskeleton and cytoskeleton (LINC) complex-chromatin cascade). Current research uses bioreactors and stiffness-tunable gels but faces challenges of unstandardized parameters, decoupled mechanical cues, and limited clinical specimens. Derived insights enable mechanomedicine innovations: novel drug targets, physical therapies (ultrasound/light-mediated ECM modulation), personalized surgical planning (computational fluid dynamics-guided valvuloplasty), optimized bioprosthetic valves, and early diagnosis (valvular elastography). Overcoming interdisciplinary barriers and standardizing methods will accelerate translation of mechanobiological findings into precision clinical strategies, addressing CAVD patients' unmet needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.